Who is sponsoring NCT04334109?

NCT04334109 is sponsored by University of Arkansas.

What drugs are being tested in NCT04334109?

Interventions in NCT04334109: Family Diabetes Self-Management Education and Support, Standard Diabetes Self-Management Education and Support.

What condition does NCT04334109 study?

NCT04334109 studies Diabetes Mellitus, Type 2.

Is NCT04334109 still recruiting?

NCT04334109 is currently completed. Last updated 3 August 2025.

Last reviewed 2025-08-03 · How we verify

NCT04334109

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Effectiveness of Family DSMES and Standard DSMES Among Diverse Populations

Completed NA Last updated 3 August 2025

What this trial tests

NA trial testing Family Diabetes Self-Management Education and Support in Diabetes Mellitus, Type 2 in 550 participants. Completed in 17 September 2024.

Timeline

4 January 2021

Primary endpoint
17 May 2023

17 September 2024

Quick facts

Lead sponsor	University of Arkansas
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	550
Start date	4 January 2021
Primary completion	17 May 2023
Estimated completion	17 September 2024
Sites	1 location across United States

Drugs / interventions tested

Family Diabetes Self-Management Education and Support
Standard Diabetes Self-Management Education and Support

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

University of Arkansas

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will conduct a fully-powered, comparative effectiveness randomized controlled trial that includes up to 600 patients with type 2 diabetes (T2D) and 600 of their family members. Patients with T2D will be randomly assigned to either the Family-DSMES arm or the Standard-DSMES arm, with 300 patients in each arm. In the Family-DSMES arm, one of each patient's family members will take part in the educational sessions (family members defined below). Baseline and follow-up data (immediate post-intervention, 6 months post-intervention, and 12 months post-intervention) will be collected from patients and family members in both study arms. In the Standard-DSMES arm, data will be collected from family members, but they will not participate in educational sessions. In both arms, the investigators will obtain a medical records release to abstract outcomes at 18 months post-intervention.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness-implementation trial comparing a family model of diabetes self-management education and support with a standard model.
Mayberry LS, Felix HC, Hudson J, Curran GM, et al · · 2022 · cited 5× · PMID 36096282 · DOI 10.1016/j.cct.2022.106921
Comparative effectiveness of telehealth-delivered family and standard models of diabetes self-management education and support for persons with type 2 diabetes mellitus.
Andersen JA, McElfish PA, Selig JP, Li J, et al · · 2026 · PMID 41429275 · DOI 10.1016/j.diabres.2025.113063

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other University of Arkansas trials

Trials by the same sponsor.

NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients · NA · not yet recruiting
NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04334109 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
Last refreshed: 3 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04334109.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing